ClearTrial® Managing Partners to Speak at DIA Annual Meeting

Share Article

Managing partners Richard K. Musselman and Michael Soenen of ClearTrial, LLC, to speak at 43rd Annual Meeting of the Drug Information Association (DIA) to be held at the Georgia World Congress Center in Atlanta, June 17-19, 2007.

Managing partners Richard K. Musselman and Michael Soenen of ClearTrial, LLC, will share their considerable expertise in the biotech and pharmaceutical industries at the 43rd Annual Meeting of the Drug Information Association (DIA) to be held at the Georgia World Congress Center in Atlanta, June 17-19. Musselman will chair "Improving CRO Negotiations to Accelerate Time to Market," a session that will examine methods for streamlining the contract process between drug developers and contract research organizations (CROs). Soenen will discuss "Transforming Five New Clinical Development Strategies into Real Results and What We Can Learn from the Industries that Have Done It."

Musselman has been a speaker and chair at numerous industry conferences and seminars for professional organizations. In his 30-year career in the pharmaceutical, biotech, and medical industries, he has become a noted expert in clinical drug development,cost management and Outsourcing. From 1997 to 2001, he served as Senior Director, R&D Contract Management and Procurement for G.D. Searle (Pfizer). Musselman has a dozen years' experience specifically within the CRO industry, having been Senior Vice President of Strategic Planning and Business Development at Springborn Laboratories (SCIREX), Director of Business Development at G.H.Besselaar (Covance). and before that a founding member of Clinical Research International a CRO in RTP, NC.

Soenen's 20-year career has focused on providing life sciences, manufacturing, and distribution companies with efficiencies in supplier relationship management (SRM), customer relationship management (CRM), complex pricing, and contract management. In the past 12 years, he has led three companies whose technology solutions have enabled some of today's leading SRM and CRM strategies. At ClearTrial, Soenen is responsible for overall operations and development of the company's clinical trial operations planning (CTOP) and outsourcing software. Previously, as President and CEO of Consolidated Commerce, Soenen led this SRM software developer to recognition as one of the top 100 innovative companies on the InformationWeek 100 (1999) and Forbes.com's Best-of-the-Web (2001).

About the DIA
The DIA is a nonprofit professional association of approximately 20,000 members worldwide, who are involved in the discovery, development, regulation, surveillance, or marketing of pharmaceuticals and related products. The organization disseminates information among its members, with the goal of continuously improving professional practice.

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information, please click the following link and read about the ClearTrial clinical trial software.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jim Grosspietsch
Visit website